journal article·2022-12Open access

Molecularly engineered tumor acidity-responsive plant toxin gelonin for safe and efficient cancer therapy

Guo-Bin Ding, Chenchen Zhu, Qian Wang, Huiyan Cao, Bin-Chun Li, Peng Yang, Roland H. Stauber, Guangjun Nie, Zhuoyu Li

Abstract

Due to the unsatisfactory therapeutic efficacy and inexorable side effects of small molecule antineoplastic agents, extensive efforts have been devoted to the development of more potent macromolecular agents with high specificity. Gelonin is a plant-derived protein toxin that exhibits robust antitumor effect via inactivating ribosomes and inhibiting protein synthesis. Nonetheless, its poor internalization ability to tumor cells has compromised the therapeutic promise of gelonin. In this study, a tumor acidity-responsive intracellular protein delivery system ─ functional gelonin (Trx-pHLIP-Gelonin, TpG) composed of a thioredoxin (Trx) tag, a pH low insertion peptide (pHLIP) and gelonin, was designed and obtained by genetic recombination technique for the first time. TpG could effectively enter into tumor cells under weakly acidic conditions and markedly suppress tumor cell proliferation via triggering cell apoptosis and inhibiting protein synthesis. Most importantly, treatment by intravenous injection into subcutaneous SKOV3 solid tumors in a mouse model showed that TpG was much more effective than gelonin in curtailing tumor growth rates with negligible toxicity. Collectively, our present work suggests that the tumor acidity-targeted delivery manner endowed by pHLIP offers a new avenue for efficient delivery of other bioactive substances to acidic diseased tissues.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Toxin Mechanisms and Immunotoxins · Bacteriophages and microbial interactions · Heat shock proteins research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (63)

Show source-provided references
1. Antineoplastic drug-free anticancer strategy enabled by host-defense-peptides-mimicking synthetic polypeptides10.1002/adma.202001108 ↗
2. Enhanced in vitro antitumor efficacy and strong anti-cell-migration activity of a hydroxycamptothecin-encapsulated magnetic nanovehicle10.1002/chem.201200765 ↗
3. Small-molecule prodrug nanoassemblies: an emerging nanoplatform for anticancer drug delivery10.1002/smll.202101460 ↗
4. Co-delivery of chemotherapeutics and proteins for synergistic therapy10.1016/j.addr.2015.10.021 ↗
5. A novel doxorubicin prodrug with GRP78 recognition and nucleus-targeting ability for safe and effective cancer therapy10.1021/acs.molpharmaceut.7b00830 ↗
6. Current strategies in extending half-lives of therapeutic proteins10.1016/j.jconrel.2019.02.016 ↗
7. Repurposing bacterial toxins for intracellular delivery of therapeutic proteins10.1016/j.bcp.2017.04.009 ↗
8. Polymers for cytosolic protein delivery10.1016/j.biomaterials.2019.119358 ↗
9. Top drugs and companies by sales in 201810.1038/d41573-019-00049-0 ↗
10. Nanotechnology for protein delivery: overview and perspectives10.1016/j.jconrel.2015.10.012 ↗
11. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies10.1038/nrd4363 ↗
12. Targeted and intracellular delivery of protein therapeutics by a boronated polymer for the treatment of bone tumors
13. Intracellular protein delivery system using a target-specific repebody and translocation domain of bacterial exotoxin10.1021/acschembio.7b00562 ↗
14. Advances on tumor-targeting delivery of cytotoxic proteins10.1021/acsptsci.9b00087 ↗
15. Nanomaterials for protein delivery in anticancer applications10.3390/pharmaceutics13020155 ↗
16. Protein delivery into the cell cytosol using non-viral nanocarriers10.7150/thno.34412 ↗
17. Engineering therapeutic proteins for cell entry: the natural approach10.1016/j.tibtech.2014.12.004 ↗
18. Turning a Luffa protein into a self-assembled biodegradable nanoplatform for multitargeted cancer therapy10.1021/acsnano.8b07079 ↗
19. Chiral protein supraparticles for tumor suppression and synergistic immunotherapy: an enabling strategy for bioactive supramolecular chirality construction10.1021/acs.nanolett.0c01757 ↗
20. On the contentious sequence and glycosylation motif of the ribosome inactivating plant protein gelonin10.1016/j.bbrc.2005.06.008 ↗
21. Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis10.1016/j.pep.2005.08.029 ↗
22. Intracellular re-localisation by photochemical internalisation enhances the cytotoxic effect of gelonin — quantitative studies in normal rat liver10.1016/j.jconrel.2009.11.017 ↗
23. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cell10.1016/S0021-9258(18)43667-8 ↗
24. Truncations of gelonin lead to a reduction in its cytotoxicity10.1016/j.tox.2006.11.074 ↗
25. Ribosome-inactivating proteins: current status and biomedical applications10.1016/j.drudis.2012.03.007 ↗
26. High-yield expression in Escherichia coli, biophysical characterization, and biological evaluation of plant toxin gelonin10.1007/s13205-018-1559-6 ↗
27. Recombinant TAT–gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction10.1002/jbm.a.35188 ↗
28. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy10.1016/j.jconrel.2014.08.030 ↗
29. PTD-modified attempts for enhanced toxin-based cancer therapy: an in vivo proof-of-concept study
30. Preparation and characterization of gelonin-melittin fusion biotoxin for synergistically enhanced anti-tumor activity10.1007/s11095-016-1959-4 ↗
31. Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity10.1016/j.jconrel.2013.08.016 ↗
32. Molecular tumor targeting of gelonin by fusion with F3 peptide10.1038/aps.2017.20 ↗
33. Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment10.1016/j.ijpharm.2017.03.072 ↗
34. Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy10.1007/s12272-017-0953-7 ↗
35. Genetic engineering and characterization of chlorotoxin-fused gelonin for enhanced glioblastoma therapy10.1080/1061186X.2018.1516221 ↗
36. Self-assembly of extracellular vesicle-like metal−organic framework nanoparticles for protection and intracellular delivery of biofunctional proteins10.1021/jacs.8b03584 ↗
37. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites10.1111/jphp.13098 ↗
38. Actively targeted nanomedicines for precision cancer therapy: concept, construction, challenges and clinical translation10.1016/j.jconrel.2020.10.003 ↗
39. A controlled-release nanocarrier with extracellular pH value driven tumor targeting and translocation for drug delivery10.1002/anie.201302557 ↗
40. Integrin αVβ3-targeted magnetic nanohybrids with enhanced antitumor efficacy, cell cycle arrest ability, and encouraging anti-cell-migration activity10.1021/am503359g ↗
41. Revisiting the Warburg effect: historical dogma versus current understanding10.1113/JP278810 ↗
42. pHLIP-mediated translocation of membrane- impermeable molecules into cells10.1016/j.chembiol.2009.06.006 ↗
43. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review10.1016/j.biomaterials.2016.01.061 ↗
44. Responsive and activable nanomedicines for remodeling the tumor microenvironment10.1038/s41596-020-00421-0 ↗
45. Targeting acidity in diseased tissues: mechanism and applications of the membrane-inserting peptide, pHLIP10.1016/j.abb.2014.11.002 ↗
46. Targeting acidic diseased tissues by pH-triggered membrane-associated peptide folding10.3389/fbioe.2020.00335 ↗
47. Smart design of a pH-responsive system based on pHLIP-modified magnetite nanoparticles for tumor MRI10.1021/acsami.1c07748 ↗
48. pH low insertion peptide (pHLIP)-decorated polymeric nanovehicle for efficient and pH-responsive siRNA translocation10.1016/j.matdes.2021.110197 ↗
49. Applications of pHLIP technology for cancer imaging and therapy10.1016/j.tibtech.2017.03.014 ↗
50. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment10.1038/nature13905 ↗
51. Robust anticancer efficacy of a biologically synthesized tumor acidity-responsive and autophagy-inducing functional Beclin 110.1021/acsami.7b17454 ↗
52. A dual pH-responsive DOX-encapsulated liposome combined with glucose administration enhanced therapeutic efficacy of chemotherapy for cancer10.2147/IJN.S303874 ↗
53. Metformin-induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy10.1021/jacs.0c00650 ↗
54. pH-dependent transmembrane activity of peptide-functionalized gold nanostars for computed tomography/photoacoustic imaging and photothermal therapy10.1021/acsami.6b13237 ↗
55. Thioredoxin as a fusion partner for production of soluble recombinant proteins in Escherichia coli10.1016/S0076-6879(00)26063-1 ↗
56. Carrier proteins for fusion expression of antimicrobial peptides in Escherichia coli10.1042/BA20090087 ↗
57. Thermal stability of proteins10.1196/annals.1363.003 ↗
58. Strategies for targeting protein therapeutics to selected tissues and cells10.1517/14712598.4.1.65 ↗
59. Intracellular delivery of proteins by nanocarriers10.2217/nnm-2016-0393 ↗
60. Targeted cancer therapy with ribosome biogenesis inhibitors: a real possibility?10.18632/oncotarget.5775 ↗
61. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies10.1158/0008-5472.CAN-09-2693 ↗
62. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies10.1038/onc.2012.612 ↗
63. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin10.1007/s00432-012-1181-7 ↗